Fred Hutch researchers present at ASCO 2015 Annual meeting

News Releases

Research highlights from the annual meeting of the American Society of Clinical Oncology

SEATTLE – May 29, 2015 – Investigators at Fred Hutchinson Cancer Research Center will share new research findings at the annual meeting of the American Society of Clinical Oncology, or ASCO, which is being held May 29–June 2 in Chicago.

New findings by Dr. Amanda Phipps regarding alcohol and colorectal cancer prognosis will be presented on Saturday.

On Sunday, Dr. Sunil Hingorani, will present the interim results of a clinical trial testing a new therapy for pancreatic cancer patients.

Dr. Jean McDougall will share, via a Monday poster session, new findings regarding costs and resource utilization associated with skeletal events, or complications, in patients with prostate cancer that has spread to the bones.

On Monday, Dr. Cameron Turtle will present data from an ongoing, early-stage clinical trial indicating that a first-of-its-kind immunotherapy is safe and feasible in certain patients with particular forms of acute lymphoblastic leukemia, non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Improving the value of PSA prostate cancer screening with “smarter” strategies and increased use of active surveillance will be addressed by Dr. Joshua Roth as he presents his findings at ASCO on Monday.

A full list of Fred Hutch researchers presenting at ASCO follows.

Oral Abstract Sessions

Amanda Phipps, M.D.
Alcohol consumption and prognosis in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance).

Session: Cancer Prevention, Genetics, and Epidemiology
Time: Saturday May 30, 1:15 PM - 4:15 PM
Location: S100bc
Abstract Number: 1508

Sunil Hingorani, M.D., Ph.D.
High response rate and PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: Interim results of a randomized phase II study.

Session: Gastrointestinal (Noncolorectal) Cancer
Time: Sunday May 31, 8:00 AM - 11:00 AM
Location: E Hall D2
Abstract Number: 4006

Cameron Turtle, M.B.B.S., Ph.D.
Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition.

Session: Developmental Therapeutics—Immunotherapy
Time: Monday June 1, 1:15 PM - 4:15 PM
Location: S406
Abstract Number: 3006

Ajay Gopal, M.D.
A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+ NHL.

Session: Developmental Therapeutics—Immunotherapy
Time: Monday June 1, 1:15 PM - 4:15 PM
Location: S406
Abstract Number: 3004

Poster Sessions

Shailender Bhatia
Pilot study of intratumoral G100, toll-like receptor-4 (TLR4) agonist, therapy in patients with Merkel cell carcinoma (MCC).

Session: Developmental Therapeutics—Immunotherapy
Time: Saturday May 30, 8:00 AM to 11:30 AM
Location: S Hall A
Poster Board #409
Abstract Number: 3083

Elahe Mostaghel, M.D., Ph.D.
Association of SLCO transport genes with intraprostatic abiraterone (ABI) levels and pathologic outcomes in men with high-risk localized prostate cancer (PCa).

Session: Genitourinary (Prostate) Cancer
Time: Saturday May 30, 1:15 PM - 4:45 PM
Location: S Hall A
Poster Board #5
Abstract Number: 5013

Hannah Richards
A functional kinome screen to identify pathways of anthracycline resistance in patient-derived breast cancer cells.

Session: Tumor Biology
Time: Sunday May 31, 8:00 AM - 11:30 AM
Location: S Hall A
Poster Board #306
Abstract Number: 11092

Scott Ramsey, M.D., Ph.D.
Quality of life EQ-5D results from the AETHERA trial: A phase III study of brentuximab vedotin consolidation following autologous stem cell transplant for HL.

Session: Health Services Research and Quality of Care
Time: Monday June 1, 1:15 PM - 4:15 PM
Location: S Hall A
Poster Board #125
Abstract Number: 6568

Jean McDougall, Ph.D.
Costs and resource utilization associated with skeletal related events in Medicare patients with prostate cancer metastatic to bones.

Session: Health Services Research and Quality of Care
Type: Poster Session
Time: Monday June 1, 1:15 PM - 4:45 PM
Location: S Hall A
Poster Board #169
Abstract Number: 6612

Joshua Roth, Ph.D., M.H.A.
Improving the value of PSA prostate cancer screening with “smarter” strategies and increased use of active surveillance.

Session: Health Services Research and Quality of Care
Time: Monday June 1, 1:15 PM - 4:45 PM
Location: S Hall A
Poster Board #173
Abstract Number: 6616

# # #

 40 YEARS OF CURES 1975-2015

At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer with minimal side effects. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first and largest cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs. For more information visit www.fredhutch.org or follow Fred Hutch on FacebookTwitter or YouTube.

MEDIA CONTACT

Michael Nank
Media Relations Manager
mnank@fredhutch.org
206.667.6906